{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T08:47:07Z","timestamp":1744793227303},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,5,22]],"date-time":"2007-05-22T00:00:00Z","timestamp":1179792000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2007,8,22]]},"DOI":"10.1007\/s12032-007-0004-1","type":"journal-article","created":{"date-parts":[[2007,5,21]],"date-time":"2007-05-21T22:54:16Z","timestamp":1179788056000},"page":"301-307","source":"Crossref","is-referenced-by-count":4,"title":["Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer"],"prefix":"10.1007","volume":"24","author":[{"given":"Thomas","family":"Makatsoris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavlos","family":"Papakostas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haralabos P.","family":"Kalofonos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Xanthakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Tsavdaridis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerasimos","family":"Aravantinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Gogas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Klouvas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paris","family":"Kosmidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Pectasides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Fountzilas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,5,22]]},"reference":[{"key":"4_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0895-4356(02)00534-6","volume":"56","author":"JR Kelley","year":"2003","unstructured":"Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003;56:1\u20139.","journal-title":"J Clin Epidemiol"},{"key":"4_CR2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/bjs.1800790404","volume":"79","author":"AJ Akoh","year":"1992","unstructured":"Akoh AJ, McIntyre IMC. Improving survival in gastric cancer: Review of 5-year survival rates in English language publications from 1970. Br J Surg 1992;79:293\u20139.","journal-title":"Br J Surg"},{"key":"4_CR3","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","volume":"24","author":"AD Wagner","year":"2006","unstructured":"Wagner AD, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903\u20139.","journal-title":"J Clin Oncol"},{"key":"4_CR4","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.1985.03350380077025","volume":"253","author":"SA Cullinan","year":"1985","unstructured":"Cullinan SA, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs. fluorouracil and doxorubicin vs fluorouracil, doxorubicin and mitomycin. JAMA 1985;253:2061\u20137.","journal-title":"JAMA"},{"key":"4_CR5","first-page":"397","volume":"23","author":"J Wils","year":"1996","unstructured":"Wils J. The treatment of advanced gastric cancer. Semin in Oncol 1996;23:397\u2013406.","journal-title":"Semin in Oncol"},{"key":"4_CR6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0959-8049(97)86090-X","volume":"15","author":"A Webb","year":"1997","unstructured":"Webb A, et al. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261\u20137.","journal-title":"J Clin Oncol"},{"key":"4_CR7","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.1992.10.4.541","volume":"10","author":"D Kelsen","year":"1992","unstructured":"Kelsen D, et al. FAMTX versus etoposide, doxorubicin and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992;10:541\u20138.","journal-title":"J Clin Oncol"},{"key":"4_CR8","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1200\/JCO.1997.15.11.3313","volume":"15","author":"S Cascinu","year":"1997","unstructured":"Cascinu S, et al. Intensive weekly chemotherapy for advanced gastric cancer using 5-fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol 1997;15:3313\u20139.","journal-title":"J Clin Oncol"},{"key":"4_CR9","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/annonc\/mdh422","volume":"15","author":"SS Wohrer","year":"2004","unstructured":"Wohrer SS, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. Ann Oncol 2004;15:1585\u201395.","journal-title":"Ann Oncol"},{"key":"4_CR10","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1200\/JCO.1998.16.6.2164","volume":"16","author":"JD Hainsworth","year":"1998","unstructured":"Hainsworth JD, Burris HA III, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998;16:2164\u20138.","journal-title":"J Clin Oncol"},{"key":"4_CR11","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1200\/JCO.2001.19.15.3500","volume":"19","author":"JD Hainsworth","year":"2001","unstructured":"Hainsworth JD, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network Phase II trial. J Clin Oncol 2001;19:3500\u20135.","journal-title":"J Clin Oncol"},{"key":"4_CR12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, et al. Reporting results of cancer treatment. Cancer 1981;47:207\u2013214.","journal-title":"Cancer"},{"key":"4_CR13","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"17","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;17:1748\u201356.","journal-title":"J Clin Oncol"},{"key":"4_CR14","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1023\/A:1008373814453","volume":"11","author":"F Graziano","year":"2000","unstructured":"Graziano F, et al. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 2000;11:1263\u20136.","journal-title":"Ann Oncol"},{"key":"4_CR15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/01.coc.0000143877.53314.9c","volume":"28","author":"JH Chun","year":"2005","unstructured":"Chun JH, et al. Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol 2005;28:188\u201394.","journal-title":"Am J Clin Oncol"},{"key":"4_CR16","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/annonc\/mdl168","volume":"17","author":"M Orditura","year":"2006","unstructured":"Orditura M, et al. Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study. Ann Oncol 2006; 17:1529\u201332.","journal-title":"Ann Oncol"},{"key":"4_CR17","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/sj.bjc.6603133","volume":"94","author":"SR Park","year":"2006","unstructured":"Park SR, et al. Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma. Br J Cancer 2006;94:1402\u20136.","journal-title":"Br J Cancer"},{"key":"4_CR18","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/0277-5379(87)90101-5","volume":"23","author":"M Beer","year":"1987","unstructured":"Beer M, et al. A phase II study of carboplatin in advanced or metastatic stomach cancer. Eur J Cancer Clin Oncol 1987;23:1565\u20137.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"4_CR19","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/0277-5379(90)90067-4","volume":"26","author":"P Preusser","year":"1990","unstructured":"Preusser P, et al. Phase II study of carboplatin in untreated inoperable advanced stomach cancer. Eur J Cancer 1990;26:1108\u20139.","journal-title":"Eur J Cancer"},{"key":"4_CR20","doi-asserted-by":"crossref","first-page":"16s","DOI":"10.1200\/jco.2005.23.16_suppl.4014","volume":"23","author":"A Elsaid","year":"2005","unstructured":"Elsaid A, Elkerm Y. Final results of a randomized phase III trial of docetaxel, carboplatin, and 5FU versus epirubicin, cisplatin and 5FU for locally advanced gastric cancer. J Clin Oncol 2005;23:16s, (abstr 4014).","journal-title":"J Clin Oncol"},{"key":"4_CR21","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1200\/JCO.1994.12.12.2687","volume":"12","author":"G Cocconi","year":"1994","unstructured":"Cocconi G, et al. Fluorouracil, doxorubicin and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: A prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1994;12:2687\u201393.","journal-title":"J Clin Oncol"},{"key":"4_CR22","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"E Cutsem Van","year":"2006","unstructured":"Van Cutsem E, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991\u20137.","journal-title":"J Clin Oncol"},{"key":"4_CR23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1634\/theoncologist.10-90003-49","volume":"10","author":"JA Ajani","year":"2005","unstructured":"Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist 2005;10:49\u201358.","journal-title":"Oncologist"},{"key":"4_CR24","doi-asserted-by":"crossref","first-page":"18s","DOI":"10.1200\/JCO.2006.06.1143","volume":"24","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, et al. Randomised multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL-2 trial. J Clin Oncol 2006;24:18s (abstr LBA4017).","journal-title":"J Clin Oncol"},{"key":"4_CR25","doi-asserted-by":"crossref","first-page":"16s","DOI":"10.1200\/jco.2005.23.16_suppl.4003","volume":"23","author":"M Dank","year":"2005","unstructured":"Dank M, Zaluski J, Barone C, et al. Randomized phase 3 trial of irinotecan (CPT-11)\u00a0+\u00a05FU\/folinic acid (FA) vs CDDP\u00a0+\u00a05FU in 1st-line advanced gastric cancer patients. J Clin Oncol 2005;23:16s (abstr 4003).","journal-title":"J Clin Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-007-0004-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-007-0004-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-007-0004-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T02:22:31Z","timestamp":1559442151000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-007-0004-1"}},"subtitle":["A Hellenic Cooperative Oncology Group (HeCOG) phase II study"],"short-title":[],"issued":{"date-parts":[[2007,5,22]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,8,22]]}},"alternative-id":["4"],"URL":"https:\/\/doi.org\/10.1007\/s12032-007-0004-1","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,22]]}}}